Table 7 Relapse and survival of outcomes in young breast cancer patients according to various molecular subtypes
Outcome | 5-year | 10-year | ||||
|---|---|---|---|---|---|---|
5-year estimate (%) | 95% CI | Total number of events | 10-year estimate (%) | 95% CI | Total number of events | |
Overall | ||||||
 LRFI | 93.3 | 91.6 to 94.7 | 61 | 90.4 | 87.9 to 92.5 | 71 |
 RRFI | 95.0 | 93.4 to 96.1 | 47 | 92.4 | 90.1 to 94.2 | 57 |
 DMFI | 83.5 | 81.1 to 85.6 | 155 | 78.3 | 75.4 to 80.9 | 186 |
 OS | 91.9 | 90.1 to 93.4 | 76 | 86.2 | 83.2 to 88.7 | 101 |
HR+/HER- | ||||||
 LRFI | 95.6 | 94.0 to 97.0 | 25 | 92.7 | 89.0 to 95.1 | 32 |
 RRFI | 95.5 | 93.4 to 97.0 | 25 | 91.9 | 88.3 to 94.5 | 34 |
 DMFI | 85.6 | 82.4 to 88.2 | 83 | 78.5 | 74.4 to 82.1 | 107 |
 OS | 94.3 | 92.0 to 95.9 | 32 | 87.6 | 83.2 to 91.0 | 49 |
HR+/HER+ | ||||||
 LRFI | 90.7 | 83.4 to 94.9 | 10 | 90.7 | 83.4 to 94.9 | 10 |
 RRFI | 94.5 | 88.0 to 97.5 | 6 | 94.5 | 88.1 to 97.5 | 6 |
 DMFI | 77.1 | 68.1 to 83.8 | 26 | 73.4 | 63.9 to 80.8 | 29 |
 OS | 87.3 | 79.5 to 92.3 | 14 | 80.3 | 68.1 to 88.3 | 17 |
HR−/HER+ | ||||||
 LRFI | 83.1 | 72.0 to 90.0 | 12 | 81.3 | 69.9 to 88.8 | 13 |
 RRFI | 91.8 | 82.7 to 96.3 | 6 | 90.0 | 80.0 to 95.1 | 7 |
 DMFI | 71.7 | 59.9 to 80.5 | 20 | 68.6 | 56.6 to 77.9 | 23 |
 OS | 77.9 | 66.5 to 85.8 | 16 | 71.4 | 56.8 to 81.8 | 18 |
HR−/HER2− | ||||||
 LRFI | 92.5 | 87.6 to 95.5 | 14 | 90.6 | 84.7 to 94.3 | 16 |
 RRFI | 94.7 | 90.4 to 97.1 | 10 | 94.7 | 90.4 to 97.1 | 10 |
 DMFI | 86.7 | 81.1 to 90.8 | 26 | 86.1 | 80.3 to 90.2 | 27 |
OS | 92.7 | 88.0 to 95.6 | 14 | 89.9 | 83.8 to 93.8 | 17 |